PTPRC and neoplasm: Beyond DCs, we examined various subpopulations of CD45+ cells and found that Iba1+ cells, CD45+CD11b+ myeloid cells, CD45+CD11b+Ly6G-Ly6C-F4/80+ tumor-associated macrophages, CD45+CD11C+ or CD45+CD11C+CD103+ DCs were not altered by WNT974+αPD1 treatment (Fig. 4B and SI Appendix, Fig. S6 A–C).